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Abstract: More antifungal agents have reached clinical use in the past two decades than at any 
other time. The echinocandins have been a welcome addition to this group, with the latest being 
anidulafungin. There are several lines of evidence to support anidulafungin’s role as primary therapy 
for the treatment of invasive candidiasis in non-neutropenic patients, and as alternative therapy to 
ﬂ  uconazole in patients with esophageal candidiasis with azole intolerance or triazole-resistant Can-
dida. Pharmacokinetic–pharmacodynamic studies in animals have demonstrated superior efﬁ  cacy, 
deﬁ  ned as maximal microbial kill, when compared to ﬂ  uconazole, regardless of the ﬂ  uconazole 
susceptibility of the Candida species. These studies, as well as dose-effect studies in patients, also 
support the currently recommended dose of anidulafungin. A well designed randomized controlled 
trial has demonstrated anidulafungin’s efﬁ  cacy in patients with invasive candidiasis. In this paper, we 
argue that anidulafungin may be preferable to ﬂ  uconazole for the treatment of candidemia. However, 
as of yet, the difference between anidulafungin and the other two licensed echinocandins as ﬁ  rst-line 
therapy for invasive candidiasis is unclear. On the other hand, there is insufﬁ  cient evidence as of 
yet to support ﬁ  rst-line use of anidulafungin in patients with neutropenia or aspergillosis.
Keywords: anidulafungin, pharmacokinetics-pharmacodynamics, efﬁ  cacy, candidiasis
Introduction to management of serious invasive 
fungal infections
Fungal infections are a growing global problem. The most common global mycoses are 
due to infections by Candida species, Cryptococcus neoformans, Aspergillus species, and 
other molds. The impact of this group of fungal infections has increased as the population 
of immunosuppressed patients has increased due to the AIDS pandemic, advances in immu-
nosuppressive therapies, invasive instrumentation of hospitalized patients, and an aging 
global population. For decades, the basis of most antifungal therapy has been the polyenes, 
speciﬁ  cally amphotericin B-based medications, the cytosine analogue 5-ﬂ  uorocytosine, 
and triazole compounds. Polyene-based therapy is plagued by the problem of toxicity. 
Azoles and 5-ﬂ  uorocytosine have the limitation of resistance emergence in yeast infections, 
especially problematic in the therapy of Candida glabrata (Nguyen et al 1996; Gumbo et al 
1999; Alexander et al 2005). Indeed, even after apparent therapeutic success with these 
agents, recurrence of infection has been noted months to years later (Nasser et al 1997; 
Clancy et al 2000; Gumbo et al 2002). Thus, development of new classes of antifungal 
agents was imperative. One class of new antifungal agents that have reached clinical use 
is that of echinocandins, of which anidulafungin is the latest member. The echinocandins 
have activity against Candida and Aspergillus species, but not C. neoformans.
History of anidulafungin
Anidulafungin is a semisynthetic product of echinocandin B, itself a fermentation 
product of the mold Aspergillus nidulans. It was developed by Eli Lily, underwent pre-
clinical and clinical development at Vicuron Pharmaceuticals, and was sold to Pﬁ  zer 
where it is marketed under the name Eraxis™. It received approval from the Food and Therapeutics and Clinical Risk Management 2008:4(1) 72
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Drug Administration in February 2006. Studies for its use in 
candidemia are continuing under the sponsorship of Pﬁ  zer.
Mode of action and spectrum of 
activity
The polymers glucan, mannose, and chitin are responsible 
for fungal cell wall shape and strength. Glucan is made up 
of 3 helically entwined glucose polymers linked by β-1,3-, 
α-1,3 or β-1,6-bonds. Anidulafungin inhibits enzyme com-
plex 1,3-β-D-glucan synthase and thereby inhibits fungal 
1,3-β-D-glucan synthesis. This leads to lysis of the fungal 
cell wall, and cell death. It is not surprising that when resis-
tance develops, whether in the laboratory or in patients with 
candidiasis, the isolates often contain a mutation in the gene 
that encodes for components of the 1,3-β-D-glucan synthase 
enzyme complex such as FKS1 and FKS-2 (Kurtz et al 
1996). Mutations in the fks1gene lead to glucan synthase 
activity that is more resistant to the effect of echinocandins 
than the wild type enzyme. Fungi that have an abundance of 
β-1,3-bonds will, in general, be susceptible to anidulafungin, 
at least in the laboratory. The susceptibility of a variety of 
fungal pathogens to anidulafungin are shown in Table 1 
(adapted and modiﬁ  ed from Gumbo et al 2007a), which sum-
marizes data from a variety of laboratory studies of clinical 
isolates (Espinel-Ingroff 1998; Oakley 1998; Espinel-Ingroff 
2003; Serrano et al 2003). Fusarium species, Trichosporon 
beigelii, Rhizopus species, and C. neoformans are resistant to 
anidulafungin. Anidulafungin has low MICs against mycelial 
forms of H. capsulatum, B. dermatitidis, and C. immitis, but 
high MICs against the yeast forms (Espinel-Ingroff 1998).
Administration, distribution,
and elimination of anidulafungin
Anidulafungin is FDA approved for the treatment of invasive 
candidiasis, candidemia and esophageal candidiasis. Recom-
mended doses and infusion volumes are shown in Table 2 
(Pﬁ  zer Inc. 2006). Anidulafungin requires a companion dilu-
ent, 20% weight/weight dehydrated alcohol, for reconstitution. 
The solution can be further diluted in either 5% dextrose or 
normal saline solutions and administered at an infusion rate not 
exceeding 1.1mg/min. The solution is compatible with most 
other intravenous solutions, with notable exceptions including 
ertapenem, sodium bicarbonate, and amphotericin B (Trissel 
and Ogundele 2005). No oral alternative is available due to 
poor oral bioavailability ( 5%), thus all recommended dosing 
is intravenous. After systemic administration of anidulafun-
gin, murine studies demonstrate that anidulafungin persists 
in tissues for many days after a single dose of anidulafungin 
(Gumbo et al 2006). The time to peak concentrations in tissue 
was markedly slower than time to peak concentrations in the 
serum. The concentrations that are achieved are proportional 
to dose, indicating linear pharmacokinetics. The volume of 
distribution in adult patients is 0.6 L/kg, close to the total body 
water volume (Dowell et al 2004)). Anidulafungin is elimi-
nated by non-enzymatic degradation from a ring form into a 
linear peptide, which is then degraded to tertiary products by 
nonspeciﬁ  c peptidases in human plasma. The serum terminal 
half-life is estimated to be nearly 1 day. Elimination of parent 
compound and degradation products is via the fecal route, with 
 1% excreted via the urine. Therefore, from a xenobiotic 
metabolism standpoint, one would not expect dose adjustments 
in patients with renal or hepatic impairment. This has been 
conﬁ  rmed in clinical studies (Dowell et al 2003).
Population pharmacokinetics 
anidulafungin
Clinicians at a patient’s bedside often need to adjust doses 
of antimicrobials to individualize antibiotic therapy, given 
the demographic and pathophysiological conditions that are 
particular to the patient. In order to achieve this successfully, 
population pharmacokinetic analysis studies need to be per-
formed to account for patient-to-patient variability, and the 
reasons for such variability. Dowell and colleagues performed 
population pharmacokinetic analysis on steady state serum 
Table 1 Susceptibility of common fungal pathogens to anidula-
fungin
Species  Number of   Anidulafungin MEC90
 isolates  tested  or  MIC90 (mg/L)
Candida species  
C. albicans   733   0.03
C. glabrata   458   0.13
C. parapsilosis   391 2
C. tropicalis   307 0.13
C. krusei   50   0.13
C. lusitaniae   20 0.25
C. dubliniensis   18 0.06
Cryptococcus
neoformans   10   16
Aspergillus species  
 A. fumigatus   28   0.03
 A. ﬂ  avus   19   0.03
 A.niger   9   0.03
 A. glaucus   8   0.03
 A. terreus   8  0.003
Penicillium species   -
Pseudoallescheria 
boydii  6 2.5
Rhizopus arrhizus 5   16Therapeutics and Clinical Risk Management 2008:4(1) 73
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concentrations of 129 patients who were being treated for a 
variety of fungal infections with anidulafungin daily infusions 
in one of three doses of 50 mg, 75 mg, or 100 mg (Dowell 
et al 2004). The clearance of anidulafungin was increased with 
increases in body weight, a diagnosis of invasive candidiasis, 
and being male. However, these particular demographic and 
pathological features could only explain 20% of the inter-
subject variability in clearance, and therefore are considered 
to be clinically insigniﬁ  cant. The implication is that there is 
no need for anidulafungin dose adjustments between patients, 
even when patients are of different weight and gender.
Pharmacokinetic-pharmacodynamic 
studies
In order to determine optimal doses and dosing schedules, 
pharmacokinetic- pharmacodynamic (PK-PD) are performed. 
In such studies, the drug exposures expressed as PK-PD indices 
such as the area under the concentration-time curve to MIC 
(AUC/MIC), peak concentration to MIC (Cmax/MIC) or the time 
that drug concentration is above the MIC (TMIC), are related to 
antimicrobial effect. If a drug’s microbial kill correlates best 
with AUC/MIC or Cmax/MIC ratio then administration of the 
same cumulative dose as intermittent doses would not compro-
mise efﬁ  cacy. However, if the drug’s efﬁ  cacy is best associated 
with TMIC, then more frequent dosing such as several times 
a day is better, while more extended dosing intervals would 
reduce efﬁ  cacy. Data on the particular PK-PD index that best 
explains anidulafungin effect have been somewhat ambiguous. 
In a rabbit model of disseminated candidiasis and pulmonary 
aspergillosis the PK-PD index associated with effect could 
not be clearly distinguished (Groll et al 2001). Drugs within 
the same pharmacological class often have effect linked to the 
same PK-PD index. When Andes et al and Wiederhold et al 
examined other echinocandin agents, namely caspofungin and 
HMR 3270, they found that the Cmax/MIC was most closely 
linked to antifungal effect (Andes et al 2003; Wiederhold 
et al 2004). We too have performed PK-PD studies of the 
echinocandins caspofungin and micafungin (Louie et al 2005; 
Gumbo et al 2007b). We found that for this class of agents, it is 
more the tissue concentration at the site of effect that correlates 
with microbial kill than that which we measure in serum. This 
has important implications in those echinocandins such as 
anidulafungin and caspofungin which persist in the tissues for 
many days, as opposed to micafungin which does not. If the 
infected animals are sacriﬁ  ced early or prior to the full effect 
of the drug being achieved, it would be difﬁ  cult to identify the 
PK-PD index most closely associated with effect. Taking this 
into consideration, we found that AUC/MIC best correlated 
with echinocandin antifungal effect. Thus, once-a-day, or even 
a dosing schedule once every few days should be efﬁ  cacious. 
More extended anidulafungin dosing intervals, though, have 
not yet been examined in clinical trials. However, every-other-
day echinocandin dosing has already been demonstrated to 
be as efﬁ  cacious as daily therapy for the sister echinocandin, 
micafungin (Buell et al 2005). In the meantime, we have per-
formed studies to determine the AUC/MIC exposure associ-
ated with optimal anidulafungin effect in mice with persistent 
neutropenia related candidemia, and compared the efﬁ  cacy 
of anidulafungin versus ﬂ  uconazole (Gumbo et al 2006). The 
AUC/MIC associated with optimal microbial effect in the 
mice, in an inhibitory sigmoid Emax analysis, was an exposure 
which is easily be achieved by a 100 mg dose in humans given 
the Candida MIC90 in clinical isolates. It is interesting that 
in an inhibitory sigmoid Emax model analysis performed by 
Krause et al one of the factors associated with optimal anidu-
lafungin therapy in patients with esophageal candidiasis was 
an AUC  35 mg*h/L (Dowell et al 2003). This exposure is 
also easily surpassed by an intravenous anidulafungin dose of 
100 mg a day in adults, which achieves a 0–24 h AUC of 110 
mg*h/L (Pﬁ  zer Inc. 2006). Importantly, in our mouse study, 
the maximal microbial kill (Emax) of anidulafungin was superior 
to that of ﬂ  uconazole, whether the Candida strain utilized was 
susceptible to ﬂ  uconazole, was susceptible-dose dependent, or 
ﬂ  uconazole resistant. Thus, in the neutropenic animal model 
anidulafungin was more efﬁ  cacious than ﬂ  uconazole.
Efﬁ  cacy of anidulafungin: evidence 
from clinical trials
Anidulafungin has been compared with fluconazole for 
the treatment of esophageal candidiasis in a randomized, 
Table 2 Recommended adult doses and infusion volumes for anidulafungin
Indication  Dosing schedule  Infusion volume
Invasive candidiasis and candidemia  200 mg intravenous loading dose, then  500 mL in loading dose; 250 mL
  100 mg iv daily  in maintenance dose
Esophageal candidiasis  100 mg intravenous loading dose, then  250 mL in loading dose; 100 mL
  50 mg iv daily  in maintenance dose
Based on package insert (Pﬁ  zer Inc. 2006).Therapeutics and Clinical Risk Management 2008:4(1) 74
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double-blind, double-dummy study (Krause et al 2004b). 
Three hundred patients with endoscopically proven esopha-
geal candidiasis were randomized to the anidulafungin arm 
and 301 to the ﬂ  uconazole arm. Patients received a 100 mg 
intravenous loading dose of anidulafungin followed by 50 mg 
iv daily, or a 200 mg loading dose of oral ﬂ  uconazole fol-
lowed by 100 mg daily for 14–21 days. Assessments such as 
endoscopic response as well as clinical and microbiologic 
response, were performed at baseline and at end of therapy, 
with the clinical and microbiologic responses also assessed 
at a follow-up visit 2 weeks after the completion of therapy. 
The most common Candida species isolated were C. albicans 
(91%) and C. glabrata (∼2%). An intent-to-treat analysis at 
the end of treatment revealed similar success rates between 
anidulafungin (86.7%) and ﬂ  uconazole (88%). However, 
at the 2-week follow up visit, nearly 36% of patients in the 
anidulafungin arm had relapsed compared to only 10.5% in the 
ﬂ  uconazole group. This problem of higher relapse in patients 
treated with anidulafungin versus ﬂ  uconazole is thrown into 
doubt by the fact that more patients in the ﬂ  uconazole arm 
(58/300) were started on antiretroviral therapy (ART) during 
antifungal therapy compared to those in the anidulafungin arm 
(26/301) (p   0.001 by our analysis). Thus, higher relapse 
rates in the anidulafungin arm could be explained by ART 
therapy, or lack thereof. On the other hand, high relapse rates 
have been seen in patients with Candida esophagitis treated 
with the other echinocandins such as caspofungin (Arathoon 
et al 2002) and micafungin (de Wet et al 2004), so that it 
is still plausible, even taking ART into consideration, that 
anidulafungin therapy could lead to higher relapse rates.
In a Phase II dose-ranging study the safety and efﬁ  cacy of 
anidulafungin in the treatment of invasive candidiasis and/or 
candidemia was evaluated in 123 patients (Krause et al 2004a). 
Adult patients were randomized to receive daily intravenous 
anidulafungin of 50 mg, 75 mg or 100 mg for up to 14 days 
after resolution of infection, following a one-time loading dose 
(double the daily dose) on the ﬁ  rst day. The most common 
isolates were C. albicans (53%), C. glabrata (31%), and C. 
parapsilosis (9%). Global response (clinical and microbiologi-
cal) rates at the end of treatment were 84% in the 50 mg group, 
90% in the 75 mg group and 89% in the 100 mg group. These 
results suggest that the dose of 100 mg a day is on the optimal 
effect portion of the dose-response curve. This is also consistent 
with animal PK-PD studies. Taken together, this indicates that 
a daily dose of 100 mg would be the optimum dose to study in 
randomized controlled studies versus standard therapy.
Fluconazole has been the standard therapy for invasive can-
didiasis in non-neutropenic patients since the early 1990s, due 
to both good efﬁ  cacy and safety (Rex et al 1994). Amphotericin 
B is equally efﬁ  cacious, but is limited by toxicity. The efﬁ  cacy 
of ﬂ  uconazole was recently compared with that of anidulafun-
gin in the treatment of invasive candidiasis (Reboli et al 2007). 
In this double-blind study, 261 patients were enrolled and then 
stratiﬁ  ed by APACHE score and presence of neutropenia. 
Patients were randomized to treatment with anidulafungin 
(200 mg loading dose then 100 mg daily) or intravenous 
ﬂ  uconazole (800 mg loading dose then 400 mg daily), with 
the option to switch to oral ﬂ  uconazole therapy after at least 
10 days of intravenous therapy. Therapy was continued for 
14 days after a negative blood culture and absence of signs 
and symptoms. The most common isolates were C. albicans 
(61.6%), C. glabrata (20.4%), and C. parapsilosis (11.8%). 
Successful outcomes were achieved in 75.6% treated with 
anidulafungin compared to 60.2% treated with ﬂ  uconazole 
group (15.4% difference, 95% conﬁ  dence interval: 3.9–27.0). 
Thus anidulafungin was superior to standard therapy. Patients 
receiving anidulafungin had higher rates of successful response 
for all Candida isolates with the exception of C. parapsilosis. 
However, the superiority of anidulafungin may be questioned 
due to a potential center effect. One center enrolled a total of 
25 patients, and 14 of 15 patients treated with anidulafungin 
(93.3%) at the center compared to 5 of 10 patients treated 
with ﬂ  uconazole (50%) had successful response. Removal of 
patients from this center makes anidulafungin non-inferior to 
ﬂ  uconazole and not superior.
Safety, tolerability, common adverse 
events
Krause et al have reported an overall adverse event rate of 
46%, but only 5% of these were directly related to the ani-
dulafungin (Krause et al 2004a). The most common adverse 
events included hypotension (13%), vomiting (13%), con-
stipation (11%), nausea (11%) and pyrexia (11%), but none 
are dose dependent. In over 1700 doses of anidulafungin 
given, no systemic infusion-related adverse reactions or 
anaphylactic reactions occurred. In another study, treatment 
related adverse events were reported in only 9.3% of patients 
(Krause et al 2004b). One patient reported subjective “ﬂ  ush-
ing” after the infusion, although no other histamine-related 
reactions have been documented. Minor elevations in hepatic 
and hematological parameters were also seen. However, in 
the recently completed invasive candidiasis trial, 15 of 127 
patients receiving anidulafungin reported an adverse event 
resulting in discontinuation of the drug (Reboli et al 2007). 
Common adverse events related to the use of anidulafungin 
are summarized in Table 3.Therapeutics and Clinical Risk Management 2008:4(1) 75
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Anidulafungin drug interactions
As discussed above, anidulafungin elimination occurs 
through non-enzymatic reactions and degradation through 
bile. Anidulafungin is not an inducer, inhibitor, or substrate, 
of the cytochrome P450 enzyme system. Therefore, little or 
no drug interactions are expected. It is not surprising, then, 
that when anidulafungin was co-administered with voricon-
azole to 18 healthy male volunteers, neither drug affected 
the other’s pharmacokinetics (Dowell et al 2005). In another 
study, cyclosporine resulted in a 22% increase in anidula-
fungin drug exposure after 4 days of therapy. However, this 
increase was judged not to be clinically signiﬁ  cant. Finally, 
no drug interactions have been found either with rifampin or 
amphotericin B (Dowell et al 2004), but no published data 
are present for interaction with other agents such as antiret-
roviral drugs that would be expected to be co-administered 
in patients with AIDS, as well as for other common problem 
agents such as phenytoin and calcium channel blockers.
Anidulafungin’s place in therapy
There are several lines of evidence to support anidulafungin’s 
role as primary antifungal therapy for candidiasis. First, 
in vitro studies have demonstrated broad susceptibility to 
anidulafungin among Candida species isolated from patients. 
Second, anidulafungin is fungicidal against Candida. This 
makes anidulafungin and other echinocandins, at least in 
theory, superior to fungistatic drugs such as ﬂ  uconazole. 
Third, in vivo PK-PD studies have demonstrated superior 
efﬁ  cacy, deﬁ  ned as maximal microbial kill, when compared 
to ﬂ  uconazole, regardless of the ﬂ  uconazole susceptibility of 
the Candida species. Fourth, there are adequate randomized 
controlled trials that have been performed to demonstrate 
anidulafungin efﬁ  cacy in patients.
The efﬁ  cacy of anidulafungin in the therapy of esophageal 
candidiasis has been compared to ﬂ  uconazole as discussed 
earlier. However, ﬂ  uconazole is still clearly the ﬁ  rst choice. 
Despite ﬂ  uconazole’s theoretical limitations, it performed 
equivalent to anidulafungin at the end of therapy time point, 
and may even be superior when it comes to relapse rates. 
Given that the largest number of patients in whom esopha-
geal candidiasis occurs is of AIDS patients who live in those 
countries of the globe that can least afford expensive therapy, 
ﬂ  uconazole is a better choice even if equal efﬁ  cacy to anidu-
lafungin were to be postulated. At the current moment, a pos-
sible role would be to use anidulafungin as alternative therapy 
to ﬂ  uconazole in those cases of poor tolerance to ﬂ  uconazole 
or esophageal candidiasis due to ﬂ  uconazole-resistant Can-
dida. However, given anidulafungin’s safety, its predictable 
pharmacokinetics, few drug – drug interactions, and primary 
efﬁ  cacy, it should probably be used ahead of amphotericin 
B as alternative therapy. The goals of therapy with anidula-
fungin, as for the ﬂ  uconazole, would be total resolution of 
Table 3 Adverse events (AE) associated with anidulafungin use in clinical trials
  Anidulafungin 50 mg  Anidulafungin 100 mg
  (Esophagitis Study)  (Candidemia Study)
 N  = 300(%)  N = 131(%)
Patients with  1 treatment-related AE  43 (14.3)  32 (24.4)
Gastrointestinal system  
Nausea 3  (1.0)  NR
Diarrhea NR  4  (3.1)
Blood and lymphatic system  
Neutropenia 3  (1.0)  NRa
Leukopenia 2  (0.7)  NR
Investigations  
Elevated γ-glutamyl transferase  4 (1.3)  NR
Elevated alanine aminotransferase  0  3 (2.3)
Elevated aspartate aminotransferase  1 (0.3)  1 (0.8)
Elevated alkaline phosphatase   NR  2 (1.5)
Elevated hepatic enzymes  NR  2 (1.5)
Nervous system  
Headache 4  (1.3)  NR
Skin and subcutaneous tissue  
Rash 3  (1.0)  NR
aNR: Not reported in study population.
Based on studies reported in Krause 2004a, 2004b.Therapeutics and Clinical Risk Management 2008:4(1) 76
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symptoms. We would like to point out that in patients with 
AIDS-associated esophagitis ART is indispensable.
Anidulafungin should be considered as part of ﬁ  rst-line 
or primary therapy for candidemia and invasive candidiasis 
in non-neutropenic patients. This is a role it occupies with 
ﬂ  uconazole and amphotericin B, as well as caspofungin 
and micafungin. The ﬁ  rst important question is whether the 
anidulafungin should be considered the ﬁ  rst choice, ahead 
of ﬂ  uconazole and amphotericin B preparations. This is a 
controversial topic, as recently pointed out by Sobel and 
Revankar (Sobel and Revankar 2007). Different experts 
will reach different conclusions. We would like to argue 
that based on safety, anidulafungin should be considered 
preferable to amphotericin-B based compounds for the treat-
ment of candidemia and invasive candidiasis. The question 
then becomes whether anidulafungin should be used ahead 
of ﬂ  uconazole. Several facts should be considered. First, a 
randomized controlled study did show superiority of anidu-
lafungin to ﬂ  uconazole in the “gold standard” intention-to-
treat analysis. Second, the rates of persistent candidemia 
at the end of therapy was 6.3% with anidulafungin versus 
14.4% with ﬂ  uconazole (p = 0.06). Third, the average global 
response rates to ﬂ  uconazole in several clinical studies of 
candidemia have been persistently around 50%–60%, except 
in the study by Rex et al in 1994, while those of 100 mg 
of anidulafungin and other echinocandins are often around 
70%–80%, or even higher (Rex et al 1994; Phillips et al 1997; 
Rex et al 2003; Krause et al 2004a; Kuse et al 2007; Reboli 
et al 2007; Pappas et al 2007). Fourth, in vivo PK-PD studies 
have demonstrated that anidulafungin is actually more efﬁ  ca-
cious than ﬂ  uconazole. On the other hand, the center effect 
in the anidulafungin randomized study cannot be discounted, 
as discussed above. In addition, efﬁ  cacy against C. krusei 
was not studied. Furthermore, the signiﬁ  cant differences in 
efﬁ  cacy between anidulafungin and ﬂ  uconazole were seen 
mainly in patients with C. albicans and C. tropicalis, with 
success rates of 81% and 93% in the anidulafungin arm 
versus 62% and 50% in the ﬂ  uconazole arm. Superiority in 
patients treated with other Candida species therefore needs 
further investigation. However, there is an ethical dimension 
to be taken into consideration if anidulafungin is a potentially 
superior therapy. Ethical principles would seem to point to 
use of anidulafungin instead of ﬂ  uconazole, given similar 
safety proﬁ  les with ﬂ  uconazole and therapy shown to be 
superior in a randomized study. Of course, in those situations 
where the patients cannot afford anidulafungin, or it is for 
some reason not available, ﬂ  uconazole should be the ﬁ  rst line 
of therapy. This brings us to a ﬁ  nal and rather fascinating 
question, which is whether other echinocandins can simply 
be substituted for anidulafungin. Caspofungin was compared 
to amphotericin B deoxycholate in a randomized controlled 
trial of patients with invasive candidiasis, and at the end of 
intravenous therapy demonstrated equivalency in the modi-
ﬁ  ed intention to treat analysis, and superiority (81% versus 
65% response) if only patients who met criteria for evaluation 
were analyzed (Mora-Duarte et al 2002). Recently, another 
randomized controlled trial compared micafungin to lipo-
somal amphotericin B in patients with invasive candidiasis, 
and demonstrated equivalence (90% versus 90% response) 
(Kuse et al 2007). Therefore, all three echinocandins have 
been demonstrated to have excellent efﬁ  cacy in the treatment 
of invasive candidiasis, and as of yet all three should be 
considered ﬁ  rst line therapy for invasive candidiasis.
In patients with candidemia and invasive candidiasis and 
neutropenia, there is insufﬁ  cient data to recommend anidula-
fungin. In the dose ranging study by Krause et al for example, 
there were only 16 of 120 (13%) patients with neutropenia, 
while in the study of anidulafungin versus ﬂ  uconazole, there 
were only 7 of 245 patients with neutropenia (Krause el al 
2007). Therefore, there is insufﬁ  cient clinical data as of yet 
to recommend anidulafungin for candidemia in patients with 
neutropenia. In these patients, micafungin, caspofungin and 
lipid preparations of amphotericin B should be used (Mora-
Duarte et al 2002; Kuse et al 2007).
There have been very few reports, if any, of the use of 
anidulafungin in the treatment of Candida endocarditis, 
chronic disseminated candidiasis, osteomyelitis, urinary 
candidiasis or meningitis. The penetration of the drug into 
bone and many such sites is still poorly deﬁ  ned, but central 
nervous system penetration is known to be poor. It is also 
expected that there would be low concentrations achieved 
in urine, so that anidulafungin is not expected to work in 
Candida urinary tract infections. However, it is intrigu-
ing that three cases have been published in which another 
echinocandin, caspofungin, was efﬁ  cacious in the treatment 
of complicated and ascending C. glabrata infection, even 
when that echinocandin also does not, in theory, achieve 
high concentrations in urine (Sobel et al 2007). However, 
prospective clinical studies with anidulafungin or any other 
echinocandin for that matter are lacking. Thus, at the present 
moment anidulafungin is not yet recommended for therapy 
at any of these sites.
Data are also lacking on the use of anidulafungin therapy 
for invasive aspergillosis. An open label, non-comparative 
study of the safety and efﬁ  cacy of anidulafungin plus lipo-
somal amphotericin B for the treatment of aspergillosis has Therapeutics and Clinical Risk Management 2008:4(1) 77
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been completed, but results have not yet been published in 
full. Details of this trial and the partial results can be found 
at Clinical Trials.gov (NCT00037206). Thus, the clinical 
utility of anidulafungin for invasive aspergillosis remains 
undeﬁ  ned.
Conclusion
Anidulafungin is a new echinocandin that has been introduced 
for use in patients with Candida and Aspergillus infections. 
Susceptibility data, in vivo PK-PD studies, and clinical stud-
ies support a role in the treatment of esophageal candidiasis 
in those patients who can not tolerate azole therapy or have 
azole-resistant Candida, and a role as ﬁ  rst-line therapy for 
treatment of candidemia and invasive blood stream infection. 
However, data are lacking for use in other clinical scenarios, 
and in treatment of invasive aspergillosis.
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